Negative symptoms and neuroleptics in catatonic schizophrenia

被引：8

作者：

Salokangas, RKR ^{[1
]}

Honkonen, T

Stengård, E

Koivisto, AM

Hietala, J

机构：

[1] Univ Turku, Dept Psychiat, FIN-20520 Turku, Finland

[2] Univ Turku, Cent Hosp, Psychiat Clin, FIN-20520 Turku, Finland

[3] Turku Mental Hlth Ctr, Turku Psychiat Clin, FIN-20700 Turku, Finland

[4] Finnish Inst Occupat Hlth, Sect Clin Neurosci, FI-00250 Helsinki, Finland

[5] Tampere Univ, Dept Psychol, FIN-33014 Tampere, Finland

[6] Tampere Univ, Tampere Univ Hosp, Res Unit, Tampere Sch Pub Hlth, FIN-33014 Tampere, Finland

[7] Univ Turku, Cent Hosp, Turku PET Ctr, FIN-20520 Turku, Finland

来源：

SCHIZOPHRENIA RESEARCH | 2003年 / 59卷 / 01期

关键词：

catatonia; schizophrenia; negative symptoms; neuroleptic medication; dopaminergic pathway;

D O I：

10.1016/S0920-9964(02)00155-X

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

The association between neuroleptic treatment and the negative symptom dimension (ND) was evaluated in 1528 schizophrenia patients. In patients receiving more than 820 mg chlorpromazine (CPZ), those with catatonic-type disorder had significantly (p < 0.05) higher ND scores than those in any of the other diagnostic subtypes. Even in patients receiving 450 mg CPZ or more, catatonic patients had significantly (p = 0.046) higher ND scores than other patients. Patients with catatonic schizophrenia are highly vulnerable to negative symptoms related to neuroleptic drugs, probably because of a defect in their dopaminergic neuronal pathways. (C) 2002 Elsevier Science B.V. All rights reserved.

引用

页码：73 / 76

页数：4

共 17 条

[1]

[Anonymous], 1986, POSITIVE NEGATIVE SY

[2]

Black KJ, 1997, J NEUROSCI, V17, P3168

[3] Catatonia and the neuroleptics: Psychobiologic significance of remote and recent findings [J].

Blumer, D .

COMPREHENSIVE PSYCHIATRY, 1997, 38 (04) :193-201

[4] Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication - A pilot study examining the role of dopamine [J].

Bodkin, JA ;

Cohen, BM ;

Salomon, MS ;

Cannon, SE ;

Zornberg, GL ;

Cole, JO .

JOURNAL OF NERVOUS AND MENTAL DISEASE, 1996, 184 (05) :295-301

[5]

CARPENTER WT, 1988, AM J PSYCHIAT, V145, P578

[6] Catatonia 2: diagnosis, management and prognosis [J].

Clark, T ;

Rickards, H .

HOSPITAL MEDICINE, 1999, 60 (11) :812-814

[7] THE 2-SYNDROME CONCEPT - ORIGINS AND CURRENT STATUS [J].

CROW, TJ .

SCHIZOPHRENIA BULLETIN, 1985, 11 (03) :471-486

[8] Presynaptic dopaminergic function in the striatum of schizophrenic patients [J].

DaoCastellana, MH ;

PaillereMartinot, ML ;

Hantraye, P ;

AttarLevy, D ;

Remy, P ;

Crouzel, C ;

Artiges, E ;

Feline, A ;

Syrota, A ;

Martinot, JL .

SCHIZOPHRENIA RESEARCH, 1997, 23 (02) :167-174

[9]

GLENBERG AJ, 1977, ARCH GEN PSYCHIAT, V34, P947

[10] PRESYNAPTIC DOPAMINE FUNCTION IN STRIATUM OF NEUROLEPTIC-NAIVE SCHIZOPHRENIC-PATIENTS [J].

HIETALA, J ;

SYVALAHTI, E ;

VUORIO, K ;

RAKKOLAINEN, V ;

BERGMAN, J ;

HAAPARANTA, M ;

SOLIN, O ;

KUOPPAMAKI, M ;

KIRVELA, O ;

RUOTSALAINEN, U ;

SALOKANGAS, RKR .

LANCET, 1995, 346 (8983) :1130-1131

← 1 2 →